Actively Recruiting
InAdvance: Surveillance, Prevention, and Interception in a Population at Risk for Cancer
Led by Dana-Farber Cancer Institute · Updated on 2025-08-07
5000
Participants Needed
1
Research Sites
465 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This research study is creating a way to collect and store specimens and information from participants who may be at an increased risk of developing cancer, or has been diagnosed with an early phase of a cancer or a family member who has a family member with a precursor condition for cancer. * The objective of this study is to identify exposures as well as clinical, molecular, and pathological changes that can be used to predict early development of cancer, malignant transformation, and risks of progression to symptomatic cancer that can ultimately be fatal. * The ultimate goal is to identify novel markers of early detection and risk stratification to drive potential therapeutic approaches to intercept progression to cancer.
CONDITIONS
Official Title
InAdvance: Surveillance, Prevention, and Interception in a Population at Risk for Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Participants with hereditary cancer risk including carriers of pathogenic germline variants or clinical cancer predisposition syndromes
- Individuals with personal or family history suggesting elevated cancer risk
- Childhood and adult cancer survivors with treatment exposures increasing cancer risk
- Documented high exposure to group 1 IARC carcinogens
- Individuals at risk for lung cancer by age over 50, smoking history over 15 pack years, or family history of lung cancer or COPD
- Participants with alcoholic liver disease, non-alcoholic steatohepatitis, or cirrhosis
- Participants with certain precursor lesions such as ductal/lobular carcinoma in situ, Barrett's esophagus, pancreatic precursor lesions, colonic dysplasia, high-grade prostatic neoplasia, and others
- Family members or healthy individuals related to at-risk participants
You will not qualify if you...
- None; there are no exclusion criteria for this study
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Dana Farber Cancer Institute
Boston, Massachusetts, United States, 02115
Actively Recruiting
Research Team
J
Jenna Beckwith, MPH
CONTACT
T
Tia Kauffman, MPH
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
4
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here